Medicine and Health

Two-year safety outcomes of iPS cell-derived mesenchymal stromal cells in acute steroid-resistant graft-versus-host disease

K. Kelly, A. J. C. Bloor, et al.

This clinical trial found that 60% of participants with steroid-resistant acute graft-versus-host disease survived after two years of treatment with iPS cell-derived mesenchymal stromal cells (CYP-001). Impressively, there were no serious adverse events or safety concerns reported, indicating that this innovative therapy is both safe and well-tolerated. This research was conducted by Kilian Kelly, Adrian J. C. Bloor, James E. Griffin, Rohini Radia, David T. Yeung, and John E. J. Rasko.